BCRX

SEC source: 0001127602-22-017144 · form4.xml · nonDerivative · entry 1

LEE KENNETH B JR · CIK 0001208570 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 37,118

F1 · shares: Automatic non-employee director grant of Restricted Stock Units pursuant to the BioCryst Pharmaceuticals, Inc. Non-Employee Director Compensation Policy (the "Director Compensation Policy"), which will vest on the first anniversary of the date of grant.

SEC source: 0001127602-22-017148 · form4.xml · derivative · entry 2

LEVIN ALAN G · CIK 0001174452 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 30,022

Underlying: Common Stock · 30,022 shares

Expires 2032-06-07

F2 · security: Automatic non-employee director grant of stock options pursuant to the Director Compensation Policy.

SEC source: 0001127602-22-017148 · form4.xml · nonDerivative · entry 1

LEVIN ALAN G · CIK 0001174452 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 16,063

F1 · shares: Automatic non-employee director grant of Restricted Stock Units pursuant to the BioCryst Pharmaceuticals, Inc. Non-Employee Director Compensation Policy (the "Director Compensation Policy"), which will vest on the first anniversary of the date of grant.

SEC source: 0001127602-22-017141 · form4.xml · derivative · entry 2

Galson Steven K · CIK 0001495328 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 30,022

Underlying: Common Stock · 30,022 shares

Expires 2032-06-07

F2 · security: Automatic non-employee director grant of stock options pursuant to the Director Compensation Policy.

SEC source: 0001127602-22-017141 · form4.xml · nonDerivative · entry 1

Galson Steven K · CIK 0001495328 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 12,866

F1 · shares: Automatic non-employee director grant of Restricted Stock Units pursuant to the BioCryst Pharmaceuticals, Inc. Non-Employee Director Compensation Policy (the "Director Compensation Policy"), which will vest on the first anniversary of the date of grant.

SEC source: 0001127602-22-017138 · form4.xml · derivative · entry 2

ASELAGE STEVE · CIK 0001221599 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 30,022

Underlying: Common Stock · 30,022 shares

Expires 2032-06-07

F2 · security: Automatic non-employee director grant of stock options pursuant to the Director Compensation Policy.

SEC source: 0001127602-22-017138 · form4.xml · nonDerivative · entry 1

ASELAGE STEVE · CIK 0001221599 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 46,594

F1 · shares: Automatic non-employee director grant of Restricted Stock Units pursuant to the BioCryst Pharmaceuticals, Inc. Non-Employee Director Compensation Policy (the "Director Compensation Policy"), which will vest on the first anniversary of the date of grant.

SEC source: 0001127602-22-016409 · form4.xml · nonDerivative · entry 1

ASELAGE STEVE · CIK 0001221599 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 33,728

F1 · security: Shares of Common Stock issued to the reporting person in lieu of 50% of the quarterly cash Board Member retainer of $11,250, prorated to $10,597.83 based on the increase in the annual retainer fee effective April 18, 2022.

SEC source: 0001127602-22-016402 · form4.xml · nonDerivative · entry 1

HEGGIE THERESA · CIK 0001760020 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 17,363

F1 · security: Shares of Common Stock issued to the reporting person in lieu of quarterly cash Board Member retainer of $11,250, prorated to $10,597.83 based on the increase in the annual retainer fee effective April 18, 2022.

SEC source: 0001127602-22-016395 · form4.xml · nonDerivative · entry 1

LEVIN ALAN G · CIK 0001174452 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,197

F1 · security: Shares of Common Stock issued to the reporting person in lieu of quarterly cash Board Member retainer of $11,250, prorated to $10,597.83 based on the increase in the annual retainer fee effective April 18, 2022.

SEC source: 0001127602-22-016390 · form4.xml · nonDerivative · entry 1

INGRAM ROBERT ALEXANDER · CIK 0001219890 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 82,138

F1 · security: Shares of Common Stock issued to the reporting person in lieu of quarterly cash Board Member retainer of $20,000, prorated to $19,347.83 based on the increase in the annual retainer fee effective April 18, 2022.

SEC source: 0001127602-22-012272 · form4.xml · derivative · entry 3

ABERCROMBIE GEORGE B · CIK 0001485939 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 5,000 shares

Expires 2022-05-23

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 10, 2021.

F2 · derivative.exercise_date: The option vested 1/12 per month for a period of 12 months, beginning on June 23, 2012.

SEC source: 0001127602-22-012272 · form4.xml · nonDerivative · entry 2

ABERCROMBIE GEORGE B · CIK 0001485939 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 10, 2021.

SEC source: 0001127602-22-012272 · form4.xml · nonDerivative · entry 1

ABERCROMBIE GEORGE B · CIK 0001485939 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,000

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 10, 2021.

SEC source: 0001127602-22-011188 · form4.xml · nonDerivative · entry 1

Thackray Helen M. · CIK 0001589725 · Chief R&D Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 136,400

F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 14, 2022.

F2 · shares: Shares sold to satisfy the reporting person's withholding obligations upon the vesting of restricted stock units granted in 2021.

F3 · price: The price in column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $16.09 to $16.27. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote.

SEC source: 0001127602-22-009124 · form4.xml · derivative · entry 4

Sheridan William P · CIK 0001439174 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 148,302 shares

Expires 2026-05-23

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001127602-22-009124 · form4.xml · nonDerivative · entry 3

Sheridan William P · CIK 0001439174 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 37,954

F2 · price: The price in column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $17.53 to $17.79. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote.

SEC source: 0001127602-22-009124 · form4.xml · nonDerivative · entry 2

Sheridan William P · CIK 0001439174 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 39,354

F1 · price: The price in column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $16.53 to $17.52. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote.

SEC source: 0001127602-22-009124 · form4.xml · nonDerivative · entry 1

Sheridan William P · CIK 0001439174 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 199,093

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001127602-22-008780 · form4.xml · nonDerivative · entry 1

Babu Yarlagadda S · CIK 0001452635 · Chief Discovery Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 230,056

F1 · price: The price in column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $17.05 to $17.27. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote.

SEC source: 0001127602-22-008047 · form4.xml · derivative · entry 3

Jones Michael L · CIK 0001800060 · Exec. Director, Finance - PAO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 2,300 shares

Expires 2022-03-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001127602-22-008047 · form4.xml · nonDerivative · entry 2

Jones Michael L · CIK 0001800060 · Exec. Director, Finance - PAO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,198

SEC source: 0001127602-22-008047 · form4.xml · nonDerivative · entry 1

Jones Michael L · CIK 0001800060 · Exec. Director, Finance - PAO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 13,498

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001127602-22-007730 · form4.xml · nonDerivative · entry 1

LEVIN ALAN G · CIK 0001174452 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,059

F1 · security: Shares of Common Stock issued to the reporting person in lieu of quarterly cash Board Member retainer of $10,000.

SEC source: 0001127602-22-007725 · form4.xml · nonDerivative · entry 1

INGRAM ROBERT ALEXANDER · CIK 0001219890 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 80,060

F1 · security: Shares of Common Stock issued to the reporting person in lieu of quarterly cash Board Member retainer of $18,750.

SEC source: 0001127602-22-007722 · form4.xml · nonDerivative · entry 1

HEGGIE THERESA · CIK 0001760020 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 16,225

F1 · security: Shares of Common Stock issued to the reporting person in lieu of quarterly cash Board Member retainer of $10,000.

SEC source: 0001127602-22-007717 · form4.xml · nonDerivative · entry 1

ASELAGE STEVE · CIK 0001221599 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 33,159

F1 · security: Shares of Common Stock issued to the reporting person in lieu of 50% of the quarterly cash Board Member retainer of $10,000.

SEC source: 0001127602-22-005295 · form4.xml · derivative · entry 3

ABERCROMBIE GEORGE B · CIK 0001485939 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,000

Underlying: Common Stock · 5,000 shares

Expires 2022-05-23

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 10, 2021.

F3 · derivative.exercise_date: The option vested 1/12 per month for a period of 12 months, beginning on June 23, 2012.

SEC source: 0001127602-22-005295 · form4.xml · nonDerivative · entry 2

ABERCROMBIE GEORGE B · CIK 0001485939 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 10, 2021.

F2 · price: The price in column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $18.00 to $18.76. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote.

SEC source: 0001127602-22-005295 · form4.xml · nonDerivative · entry 1

ABERCROMBIE GEORGE B · CIK 0001485939 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,000

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 10, 2021.

SEC source: 0001171843-22-000942 · ownership.xml · derivative · entry 1

SANDERS MACHELLE · CIK 0001718020 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 26,667

Underlying: Common Stock · 26,667 shares

Expires 2032-02-08

F1 · shares: Automatic non-employee director grant pursuant to the BioCryst Pharmaceuticals, Inc. Amended and Restated Stock Incentive Plan.

F2 · derivative.exercise_date: The option vests 1/36 per month for a period of 36 months, beginning on March 8, 2022.

SEC source: 0001127602-22-001458 · form4.xml · derivative · entry 5

Stonehouse Jon P · CIK 0001385496 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 184,000 shares

Expires 2022-03-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 10, 2021. The options were originally granted to the reporting person on March 1, 2012 and would have expired on March 1, 2022.

SEC source: 0001127602-22-001458 · form4.xml · nonDerivative · entry 2

Stonehouse Jon P · CIK 0001385496 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 901,602

F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 10, 2021. The options were originally granted to the reporting person on March 1, 2012 and would have expired on March 1, 2022.

F2 · price: The price in column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $15.00 to $15.10. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote.

SEC source: 0001127602-22-001458 · form4.xml · nonDerivative · entry 1

Stonehouse Jon P · CIK 0001385496 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,085,602

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 10, 2021. The options were originally granted to the reporting person on March 1, 2012 and would have expired on March 1, 2022.

SEC source: 0001127602-21-031141 · form4.xml · derivative · entry 2

Jones Michael L · CIK 0001800060 · Exec. Director, Finance - PAO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,700

Underlying: Common Stock · 11,700 shares

Expires 2031-12-14

F2 · shares: Annual Employee Option Grant becomes exercisable at the rate of 25% on each of the first, second, third and fourth anniversaries of the date of grant.

SEC source: 0001127602-21-031141 · form4.xml · nonDerivative · entry 1

Jones Michael L · CIK 0001800060 · Exec. Director, Finance - PAO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,198

F1 · shares: Annual award of Restricted Stock Units which will vest 25% on each of the first, second, third and fourth anniversaries of the date of grant.

SEC source: 0001127602-21-031118 · form4.xml · derivative · entry 2

Sheridan William P · CIK 0001439174 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 164,000

Underlying: Common Stock · 164,000 shares

Expires 2031-12-14

F2 · shares: Annual Employee Option Grant becomes exercisable at the rate of 25% on each of the first, second, third and fourth anniversaries of the date of grant.

SEC source: 0001127602-21-031118 · form4.xml · nonDerivative · entry 1

Sheridan William P · CIK 0001439174 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 50,791

F1 · shares: Annual award of Restricted Stock Units which will vest 25% on each of the first, second, third and fourth anniversaries of the date of grant.

SEC source: 0001127602-21-031137 · form4.xml · derivative · entry 2

Gayer Charles K · CIK 0001800110 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 164,000

Underlying: Common Stock · 164,000 shares

Expires 2031-12-14

F2 · shares: Annual Employee Option Grant becomes exercisable at the rate of 25% on each of the first, second, third and fourth anniversaries of the date of grant.

SEC source: 0001127602-21-031137 · form4.xml · nonDerivative · entry 1

Gayer Charles K · CIK 0001800110 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 261,556

F1 · shares: Annual award of Restricted Stock Units which will vest at the rate of 25% on each of the first, second, third and fourth anniversaries of the date of grant.

SEC source: 0001127602-21-031134 · form4.xml · derivative · entry 2

Babu Yarlagadda S · CIK 0001452635 · Chief Discovery Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 164,000

Underlying: Common Stock · 164,000 shares

Expires 2031-12-14

F2 · shares: Annual Employee Option Grant becomes exercisable at the rate of 25% of each of the first, second, third and fourth anniversaries of the date of grant.

SEC source: 0001127602-21-031134 · form4.xml · nonDerivative · entry 1

Babu Yarlagadda S · CIK 0001452635 · Chief Discovery Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 250,056

F1 · shares: Annual award of Restricted Stock Units which will vest 25% on each of the first, second, third and fourth anniversaries of the date of grant.

SEC source: 0001127602-21-031130 · form4.xml · derivative · entry 2

Thackray Helen M. · CIK 0001589725 · Chief R&D Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 205,000

Underlying: Common Stock · 205,000 shares

Expires 2031-12-14

F2 · shares: Annual Employee Option Grant becomes exercisable at the rate of 25% on each of the first, second, third and fourth anniversaries of the date of grant.

SEC source: 0001127602-21-031130 · form4.xml · nonDerivative · entry 1

Thackray Helen M. · CIK 0001589725 · Chief R&D Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 144,000

F1 · shares: Annual award of Restricted Stock Units which will vest 25% on each of the first, second, third and fourth anniversaries of the date of grant.

SEC source: 0001127602-21-031126 · form4.xml · derivative · entry 2

Barnes Alane P · CIK 0001584348 · Chief Legal Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 164,000

Underlying: Common Stock · 164,000 shares

Expires 2031-12-14

F2 · shares: Annual Employee Option Grant becomes exercisable at the rate of 25% on each of the first, second, third and fourth anniversaries of the date of grant.

SEC source: 0001127602-21-031126 · form4.xml · nonDerivative · entry 1

Barnes Alane P · CIK 0001584348 · Chief Legal Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 221,969

F1 · shares: Annual award of Restricted Stock Units which will vest 25% on each of the first, second, third and fourth anniversaries of the date of grant.

SEC source: 0001127602-21-031121 · form4.xml · derivative · entry 2

Doyle Anthony · CIK 0001808688 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 164,000

Underlying: Common Stock · 164,000 shares

Expires 2031-12-14

F2 · shares: Annual Employee Option Grant becomes exercisable at the rate of 25% on each of the first, second, third and fourth anniversaries of the date of grant.

SEC source: 0001127602-21-031121 · form4.xml · nonDerivative · entry 1

Doyle Anthony · CIK 0001808688 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 208,719

F1 · shares: Annual award of Restricted Stock Units which will vest 25% on each of the first, second, third and fourth anniversaries of the date of grant.

SEC source: 0001127602-21-031116 · form4.xml · derivative · entry 6

Stonehouse Jon P · CIK 0001385496 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 574,500

Underlying: Common Stock · 574,500 shares

Expires 2031-12-14

F4 · shares: Annual Employee Option Grant becomes exercisable at the rate of 25% on each of the first, second, third and fourth anniversaries of the date of grant.

SEC source: 0001127602-21-031116 · form4.xml · nonDerivative · entry 5

Stonehouse Jon P · CIK 0001385496 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 901,602

F3 · shares: Annual award of Restricted Stock Units which will vest 25% on each of the first, second, third and fourth anniversaries of the date of grant.